Listed

Standard Biotools Inc.: Form 10-Q for the period ended Sep 30, 2013

Filed with the SEC on Nov 7, 2013 and accepted by EDGAR at Nov 7, 2013, 17:27 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-07-01 to 2013-09-30$18.3mus-gaap:Revenues
Revenue9 months2013-01-01 to 2013-09-30$50.3mus-gaap:Revenues
Cost of revenue3 months2013-07-01 to 2013-09-30$5.1mus-gaap:CostOfGoodsSold
Cost of revenue9 months2013-01-01 to 2013-09-30$14.3mus-gaap:CostOfGoodsSold
Research and development3 months2013-07-01 to 2013-09-30$5.0mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2013-01-01 to 2013-09-30$14.2mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2013-07-01 to 2013-09-30$12.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2013-01-01 to 2013-09-30$34.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2013-07-01 to 2013-09-30−$5.0mus-gaap:OperatingIncomeLoss
Operating income9 months2013-01-01 to 2013-09-30−$14.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2013-07-01 to 2013-09-30$1.0kus-gaap:InterestExpense
Interest expense9 months2013-01-01 to 2013-09-30$13.0kus-gaap:InterestExpense
Income tax3 months2013-07-01 to 2013-09-30$42.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2013-01-01 to 2013-09-30$95.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2013-07-01 to 2013-09-30−$4.3mus-gaap:NetIncomeLoss
Net income9 months2013-01-01 to 2013-09-30−$11.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2013-07-01 to 2013-09-30−$0.17us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2013-01-01 to 2013-09-30−$0.47us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2013-01-01 to 2013-09-30−$4.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2013-01-01 to 2013-09-30$1.6mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2013-09-30$20.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-09-30$86.7mus-gaap:AssetsCurrent
Total assetsAt period end2013-09-30$114.2mus-gaap:Assets
Current liabilitiesAt period end2013-09-30$15.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-09-30$17.2mus-gaap:Liabilities
Shareholders' equityAt period end2013-09-30$97.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001445305-13-002845. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.